Eli Lilly’s Forecast Surge Highlights Global Obsession and Controversy Over Weight-Loss Drugs
Eli Lilly has raised its full-year revenue and profit forecasts after booming sales of its weight-loss and diabetes medications, Zepbound and Mounjaro, propelled earnings beyond expectations. The company’s shares jumped sharply in premarket trading, reflecting growing investor confidence in the power of a new class of metabolic treatments that have rapidly transformed the healthcare landscape.…









